NL8402898A - 2,5-tweevoudig gesubstitueerde 4(3h)-pyrimidonen met histamine h2-receptor antagonistwerking. - Google Patents

2,5-tweevoudig gesubstitueerde 4(3h)-pyrimidonen met histamine h2-receptor antagonistwerking. Download PDF

Info

Publication number
NL8402898A
NL8402898A NL8402898A NL8402898A NL8402898A NL 8402898 A NL8402898 A NL 8402898A NL 8402898 A NL8402898 A NL 8402898A NL 8402898 A NL8402898 A NL 8402898A NL 8402898 A NL8402898 A NL 8402898A
Authority
NL
Netherlands
Prior art keywords
compound
formula
pyrimidone
alkyl
acid addition
Prior art date
Application number
NL8402898A
Other languages
English (en)
Dutch (nl)
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of NL8402898A publication Critical patent/NL8402898A/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NL8402898A 1983-09-21 1984-09-21 2,5-tweevoudig gesubstitueerde 4(3h)-pyrimidonen met histamine h2-receptor antagonistwerking. NL8402898A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/534,426 US4772704A (en) 1983-09-21 1983-09-21 2,5-disubstituted-4(3H)-pyrimidones having histamine H2 -receptor antagonist activity
US53442683 1983-09-21

Publications (1)

Publication Number Publication Date
NL8402898A true NL8402898A (nl) 1985-04-16

Family

ID=24129972

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8402898A NL8402898A (nl) 1983-09-21 1984-09-21 2,5-tweevoudig gesubstitueerde 4(3h)-pyrimidonen met histamine h2-receptor antagonistwerking.

Country Status (36)

Country Link
US (1) US4772704A (es)
JP (1) JPH0643310B2 (es)
KR (1) KR900001198B1 (es)
AR (2) AR242385A1 (es)
AT (1) AT387965B (es)
AU (1) AU583479B2 (es)
BE (1) BE900652A (es)
CA (1) CA1260463A (es)
CH (1) CH665840A5 (es)
CS (1) CS249147B2 (es)
CY (1) CY1561A (es)
DD (1) DD226881A5 (es)
DE (1) DE3434578A1 (es)
DK (1) DK162987C (es)
ES (4) ES8607253A1 (es)
FI (1) FI83868C (es)
FR (1) FR2552082B1 (es)
GB (1) GB2146994B (es)
GR (1) GR80439B (es)
HK (1) HK73790A (es)
HU (1) HU193227B (es)
IE (1) IE58083B1 (es)
IL (1) IL72990A (es)
IT (1) IT1176739B (es)
LU (1) LU85550A1 (es)
NL (1) NL8402898A (es)
NO (1) NO161561C (es)
NZ (1) NZ209572A (es)
OA (1) OA07820A (es)
PT (1) PT79256B (es)
SE (1) SE463209B (es)
SG (1) SG60890G (es)
YU (1) YU45205B (es)
ZA (1) ZA847345B (es)
ZM (1) ZM4984A1 (es)
ZW (1) ZW16084A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873340B2 (ja) * 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質tan―1057,その製造法および用途
EP4196793A1 (en) 2020-08-11 2023-06-21 Université de Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN151188B (es) * 1978-02-13 1983-03-05 Smith Kline French Lab
ES477520A1 (es) * 1978-02-25 1979-06-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevas penicilinas.
PH16240A (en) * 1978-04-11 1983-08-11 Smith Kline French Lab Process for making histamine antagonist
US4496567A (en) * 1978-11-13 1985-01-29 Smith Kline & French Laboratories Limited Phenyl alkylaminopyrimidones
US4521418A (en) * 1979-02-21 1985-06-04 Smith Kline & French Laboratories Limited Guanidinothiazolyl derivatives
AU531142B2 (en) * 1979-04-04 1983-08-11 Smith Kline & French Laboratories Limited 2 amino- pyimindones
CA1140129A (en) * 1979-08-21 1983-01-25 Ronald J. King 4-pyrimidone derivatives
ZW21281A1 (en) * 1980-10-01 1981-11-18 Smith Kline French Lab Amine derivatives
US4352933A (en) * 1981-02-06 1982-10-05 Smithkline Beckman Corporation Chemical methods and intermediates for preparing substituted pyrimidinones
US4468399A (en) * 1981-12-28 1984-08-28 Eli Lilly And Company 2-[2-(2-Aminoalkyl-4-thiazolylmethylthio)alkyl]-amino-5-substituted-4-pyrimidones
NZ202797A (en) * 1981-12-28 1985-08-30 Lilly Co Eli Pyrimidine derivatives and pharmaceutical compositions
GB8320505D0 (en) * 1983-07-29 1983-09-01 Smith Kline French Lab Chemical compounds
CA1275097A (en) * 1984-10-02 1990-10-09 Fujio Nohara Pyridyloxy derivatives

Also Published As

Publication number Publication date
CA1260463A (en) 1989-09-26
JPS6087271A (ja) 1985-05-16
NO843726L (no) 1985-03-22
AR242789A1 (es) 1993-05-31
US4772704A (en) 1988-09-20
KR850002259A (ko) 1985-05-10
IE58083B1 (en) 1993-06-30
DD226881A5 (de) 1985-09-04
SE8404729D0 (sv) 1984-09-20
GR80439B (en) 1985-01-22
PT79256A (en) 1984-10-01
ZA847345B (en) 1985-06-26
HU193227B (en) 1987-08-28
CH665840A5 (de) 1988-06-15
AU3335184A (en) 1985-03-28
ES551500A0 (es) 1987-03-16
FI843643A0 (fi) 1984-09-18
FI843643L (fi) 1985-03-22
NO161561B (no) 1989-05-22
NZ209572A (en) 1988-05-30
AT387965B (de) 1989-04-10
GB8423863D0 (en) 1984-10-24
DK450484A (da) 1985-03-22
ES8607253A1 (es) 1986-05-16
HK73790A (en) 1990-09-28
IE842406L (en) 1985-03-21
AU583479B2 (en) 1989-05-04
PT79256B (en) 1986-11-20
YU161384A (en) 1987-12-31
ES536054A0 (es) 1986-05-16
ES8702897A1 (es) 1987-01-16
IT8422744A0 (it) 1984-09-20
FI83868C (fi) 1991-09-10
DK450484D0 (da) 1984-09-20
ES551501A0 (es) 1987-01-16
DE3434578A1 (de) 1985-04-11
ZW16084A1 (en) 1985-01-16
DK162987C (da) 1992-06-01
CY1561A (en) 1991-03-22
IL72990A (en) 1990-07-12
CS249147B2 (en) 1987-03-12
DK162987B (da) 1992-01-06
AR242385A1 (es) 1993-03-31
OA07820A (fr) 1986-11-20
GB2146994A (en) 1985-05-01
ZM4984A1 (en) 1985-05-21
SE463209B (sv) 1990-10-22
KR900001198B1 (ko) 1990-02-28
LU85550A1 (fr) 1985-06-04
SG60890G (en) 1990-09-07
SE8404729L (sv) 1985-03-22
YU45205B (en) 1992-05-28
BE900652A (fr) 1985-03-21
ATA300984A (de) 1988-09-15
GB2146994B (en) 1987-09-03
HUT35259A (en) 1985-06-28
JPH0643310B2 (ja) 1994-06-08
FR2552082B1 (fr) 1987-02-20
IT8422744A1 (it) 1986-03-20
FI83868B (fi) 1991-05-31
ES8704465A1 (es) 1987-04-01
IT1176739B (it) 1987-08-18
ES544213A0 (es) 1987-04-01
ES8704155A1 (es) 1987-03-16
NO161561C (no) 1989-08-30
FR2552082A1 (fr) 1985-03-22

Similar Documents

Publication Publication Date Title
US4390701A (en) 1-Amino-2-[3-(3-piperidinomethylphenoxy)propylamino]cyclobutene-3,4-dione
FI89265B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara substituerade piperazinylpyridiner eller piperazinylimidazoler
SU1400508A3 (ru) Способ получени производных арилтиазолов
US4673675A (en) 1-(2-pyridyl) 4-cycloalkylmethyl piperazines having cardiotropic activity
EP0017484A1 (en) 2-Imidazoline derivatives, process for the preparation thereof and the pharmaceutical composition of the same
HU193581B (en) Process for producing amino-pyrimidine derivatives and pharmaceutical compositions containing them
US4522943A (en) Chemical compounds
US3959272A (en) Aminoalkyl esters of 2-anilino-nicotinic acids
US4395553A (en) Chemical compounds
NL8402898A (nl) 2,5-tweevoudig gesubstitueerde 4(3h)-pyrimidonen met histamine h2-receptor antagonistwerking.
US4526973A (en) Chemical compounds
US4503051A (en) Substituted 3-cyclobutene-1,2-diones, pharmaceutical compositions thereof and methods of use
US4539316A (en) Pyridine derivatives of 1,2-diaminocyclobutene-3,4-diones
DE3044566A1 (de) N-substituierte imidazol-derivate, ihre herstellung, diese enthaltende arzneimittel und ihre verwendung
KR860000103B1 (ko) 3'-치환-5'-(2-아미노-4-피리딜)-1', 2', 4'-트리아졸류의 제조 방법
SK278141B6 (en) Enolether amide 1,1-dioxo-6-chloro-4-hydroxy-2-methyl-n- -(2-pyridyl)-2h-thieno(2,3-e)1,2-thiazine-3-carboxylic acid, method of its production and pharmaceutical agent
US4546188A (en) Substituted 1,2-diaminocyclobutene-3,4-diones
US4371737A (en) 5-Aminomethyl-2,3-dihydro-2-oxo-1H-imidazole-4-carboxylic acid derivatives
AU732722B2 (en) 2-{4-{4-(4,5-dichloro-2- methylimidazol-1-yl)butyl} -1-piperazinyl}-5-fluoropyrimidine, its preparation and its therapeutic use
US4788184A (en) Substituted 3-cyclobutene-1,2-diones as anti-ulcer agents
WO2023235326A1 (en) Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors
GB2094300A (en) 4-(5)-alkylmercaptoimidazole derivatives, a process for their production and medicaments containing these compounds
CS249150B2 (cs) Způsob výroby 2,5-disubstituovaných 4 (3H)-pyrimidonů
GB2147899A (en) Chemical intermediates derived from cyclobutene
CZ9904266A3 (cs) 2-[4-[4-(4,5-dichlor-2-methylimidazol-l-yl)butyl]- l-piperazinyI]-5-fluorpyrimidin, jeho příprava a terapeutické použití

Legal Events

Date Code Title Description
DNT Communications of changes of names of applicants whose applications have been laid open to public inspection

Free format text: BRISTOL-MYERS SQUIBB COMPANY

BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
BV The patent application has lapsed